Genocea Biosciences (NASDAQ:GNCA – Get Rating) and bluebird bio (NASDAQ:BLUE – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Institutional & Insider Ownership
9.3% of Genocea Biosciences shares are held by institutional investors. Comparatively, 78.3% of bluebird bio shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 2.9% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Get Genocea Biosciences alerts:Profitability
This table compares Genocea Biosciences and bluebird bio's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genocea Biosciences | N/A | -182.88% | -62.76% |
| bluebird bio | -2,141.34% | -130.19% | -73.31% |
Earnings & Valuation
This table compares Genocea Biosciences and bluebird bio's top-line revenue, earnings per share and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genocea Biosciences | $1.64 million | 0.21 | -$33.20 million | ($0.61) | -0.01 |
| bluebird bio | $3.66 million | 125.80 | -$819.38 million | ($8.32) | -0.72 |
Genocea Biosciences has higher earnings, but lower revenue than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Genocea Biosciences and bluebird bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genocea Biosciences | 0 | 2 | 0 | 0 | 2.00 |
| bluebird bio | 2 | 8 | 1 | 0 | 1.91 |
Genocea Biosciences currently has a consensus price target of $3.00, indicating a potential upside of 50,747.46%. bluebird bio has a consensus price target of $8.50, indicating a potential upside of 42.38%. Given Genocea Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Genocea Biosciences is more favorable than bluebird bio.
Risk & Volatility
Genocea Biosciences has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
Summary
Genocea Biosciences beats bluebird bio on 8 of the 14 factors compared between the two stocks.
About Genocea Biosciences
(Get Rating)
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
About bluebird bio
(Get Rating)
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.